3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
35
Plasma cell
33
Other hematologic neoplasm
7
Thoracic
1
Sarcoma
1
Myeloid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
12
Sezary Syndrome
8
Mycosis Fungoides
8
Melanoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Large-Cell, Anaplastic
5
Immunoblastic Lymphadenopathy
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Follicular
4
Lymphoma, Extranodal NK-T-Cell
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Burkitt Lymphoma
4
Waldenstrom Macroglobulinemia
3
Neoplasm Metastasis
3
Lymphoma, T-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Intraocular Lymphoma
3
Hodgkin Disease
3
Uveal Melanoma
2
Lymphoma
2
Leukemia, Prolymphocytic
2
Leukemia, Large Granular Lymphocytic
2
Leukemia, Hairy Cell
2
Stomach Neoplasms
1
Recurrence
1
Interventions
Peripheral Blood Stem Cell Transplantation
23
fludarabine phosphate
20
Cyclophosphamide
18
Mycophenolic Acid
16
Whole-Body Irradiation
15
Cyclosporine
15
Busulfan
12
Tacrolimus
11
Methotrexate
10
Antilymphocyte Serum
9
Radiotherapy
8
Melphalan
8
Etoposide
8
pembrolizumab
7
Methylprednisolone
6
Filgrastim
6
Sirolimus
4
Prednisone
4
Nivolumab
4
sargramostim
3
Vincristine
3
Transplantation
3
Therapeutics
3
Polymerase Chain Reaction
3
Cord Blood Stem Cell Transplantation
3
Amplified Fragment Length Polymorphism Analysis
3
mogamulizumab
2
merphos
2
bempegaldesleukin
2
Voriconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Lenalidomide
×
Dermatologic
×
Clear all
NCT03302728
2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1
Completed
6 enrolled